Idiopathic Pulmonary Fibrosis Serum

Human Idiopathic Pulmonary Fibrosis Serum for Fibrosis Research

Our Idiopathic Pulmonary Fibrosis (IPF) Serum is sourced from IRB-consented donors clinically diagnosed with idiopathic pulmonary fibrosis. Each sample is processed and frozen within 24 hours of collection to keep labile analytes and matrix-turnover fragments consistent from lot to lot. Serum is acellular and is supplied here for soluble-analyte work: immunoassay, matrix-fragment quantification, proteomics and metabolomics.

Why IPF Serum for Fibrosis Research

IPF is a progressive fibrosing interstitial lung disease, not an autoimmune condition. Repeated injury to the alveolar epithelium in a susceptible, typically ageing lung provokes aberrant repair: fibroblasts are recruited and differentiate into myofibroblasts, which deposit excess collagen and other extracellular matrix, progressively stiffening the lung and destroying gas-exchange architecture. Fragments and mediators of that matrix-remodelling programme reach the circulation and are measurable in serum.

• Epithelial injury markers — surfactant proteins A and D and KL-6/MUC1 are released from damaged or regenerating alveolar epithelium and are among the most studied circulating markers in IPF.
• Matrix remodelling and collagen turnover — matrix metalloproteinases including MMP-7, their tissue inhibitors, and neoepitope collagen fragments report directly on active fibrogenesis.
• Profibrotic mediators — TGF-β is the central profibrotic cytokine, with CTGF, PDGF and the CCL18 macrophage-derived axis contributing to fibroblast recruitment and activation.
• Fibroblast-to-myofibroblast transition — the soluble outputs of this transition are the mechanistic targets of current and investigational antifibrotic agents.
• Progression and acute exacerbation biology — IPF follows a variable course punctuated by acute exacerbations, and serum offers a practical route to markers that distinguish stable from rapidly progressive disease.
• Serum-specific advantage — serum is the conventional matrix for established clinical chemistry and immunoassay platforms, easing comparison with legacy IPF biomarker datasets.

Donor Stratification Available

• Physiological severity — donors graded by forced vital capacity and diffusing capacity where documented
• Radiological or histopathological pattern — definite usual interstitial pneumonia pattern versus probable or indeterminate, subject to documentation
• Disease trajectory — stable, slowly progressive, and rapidly progressive donors; samples drawn during acute exacerbation where available
• Treatment status — treatment-naive donors and donors on antifibrotic therapy, with serial draws where collected
• Comorbidity and exposure — pulmonary hypertension, emphysema-fibrosis overlap, gastro-oesophageal reflux, and smoking history
• Matched healthy controls available, age- and sex-matched; other interstitial lung disease comparator donors also available

Product Features

• Collected from clinically confirmed idiopathic pulmonary fibrosis donors
• Research Use Only (RUO)
• Processed and frozen within 24 hours of collection
• IRB-approved protocols with documented consent
• Standard and custom aliquot volumes; volumes reported per lot

De-identified Donor Data

• Diagnosis confirmation
• Age, sex assigned at birth, and ethnicity
• Donor-reported medical history and comorbidities
• Lung function values and antifibrotic treatment context reported per lot where captured
• Additional IPF-specific clinical fields available on request

Applications

• Epithelial injury marker quantification including KL-6 and surfactant proteins
• MMP-7 and matrix metalloproteinase immunoassay development
• Collagen neoepitope and matrix turnover fragment profiling
• Profibrotic mediator measurement including TGF-β pathway outputs and CCL18
• Progression and acute exacerbation biomarker discovery
• Antifibrotic pharmacodynamic and target engagement readout development
• Serum proteomic and metabolomic discovery in pulmonary fibrosis
• Diagnostic reference and control material sourcing for interstitial lung disease assays

Other Idiopathic Pulmonary Fibrosis Specimen Types

• Idiopathic Pulmonary Fibrosis Plasma
• Idiopathic Pulmonary Fibrosis PBMC
• Idiopathic Pulmonary Fibrosis Whole Blood
• Pulmonary Fibrosis Serum
• Interstitial Lung Disease Whole Blood

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Idiopathic pulmonary fibrosis serum is available in standard and custom volumes. For pricing, international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare collection formats or check wider availability, visit our human serum page.